Oh my. Now another American desiccated thyroid (NDT) brand recall? Earlier this year, Acella’s NP thyroid was found to be superpotent (over 110% on the T3 content), and they issued a voluntary recall. Now, as of August 25, 2020, Nature-Throid… Read More ›
Acella, the makers of NP Thyroid, issued a voluntary recall notice on May 22, 2020. This is part 2 of a two-part series reviewing the drug recall notice’s statements and the science behind them. [Part 1: Acella NP Thyroid recall:… Read More ›
Acella, the makers of NP Thyroid, issued a voluntary recall notice on May 22, 2020. This is part 1 of a two-part series reviewing the drug recall notice’s statements and the science behind them. In this post, I put this… Read More ›
In this review, I outline the strengths and weaknesses of Hoang et al’s clinical trial of levothyroxine (LT4) and desiccated thyroid extract (here called DTE, also known as NDT, natural desiccated thyroid).
A clinical trial comparing Armour Thyroid (NDT) and Levothyroxine (LT4) is now recruiting patients in the United States. The sponsor of the study is Allergan, the makers of Armour Thyroid in the United States. They hope to recruit 220 patients… Read More ›
Lack of knowledge about Free T3 peaks and valleys contributes to failure and frustration in T3-based therapies, including desiccated thyroid and T3-T4 combination therapy. On patient support groups, I often see conversations that go like this: “My FT3 result was… Read More ›
Sigh. Just sigh. Even some of our best thyroid patient advocates can unknowingly share misinformation about thyroid therapy. Mary Shomon’s thyroid articles on Verywell.com are usually to be trusted. But yesterday I was saddened to see that an article supposedly… Read More ›
This post continues my paraphrase of Jonklaas et al’s 2014 “Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement.” Posts in this series: 2014 ATA Thyroid therapy guidelines: 1. Levothyroxine 2014… Read More ›